Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
SY vs SKIN vs ESTA vs INMD vs ALGN
Revenue, margins, valuation, and 5-year total return — side by side.
Household & Personal Products
Medical - Devices
Medical - Devices
Medical - Devices
SY vs SKIN vs ESTA vs INMD vs ALGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Household & Personal Products | Medical - Devices | Medical - Devices | Medical - Devices |
| Market Cap | $198M | $118M | $2.12B | $882M | $12.06B |
| Revenue (TTM) | $1.43B | $296M | $211M | $375M | $4.10B |
| Net Income (TTM) | $-741M | $-6M | $-51M | $87M | $430M |
| Gross Margin | 51.6% | 64.9% | 69.3% | 77.8% | 67.7% |
| Operating Margin | -53.2% | -3.6% | -18.5% | 21.3% | 14.4% |
| Forward P/E | — | — | — | 9.6x | 14.9x |
| Total Debt | $240M | $379M | $264M | $13M | $114M |
| Cash & Equiv. | $588M | $233M | $76M | $303M | $1.08B |
SY vs SKIN vs ESTA vs INMD vs ALGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| So-Young Internatio… (SY) | 100 | 23.7 | -76.3% |
| The Beauty Health C… (SKIN) | 100 | 9.0 | -91.0% |
| Establishment Labs … (ESTA) | 100 | 277.7 | +177.7% |
| InMode Ltd. (INMD) | 100 | 64.6 | -35.4% |
| Align Technology, I… (ALGN) | 100 | 35.0 | -65.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SY vs SKIN vs ESTA vs INMD vs ALGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SY is the #2 pick in this set and the best alternative if dividends and momentum is your priority.
- 1.6% yield; 1-year raise streak; the other 4 pay no meaningful dividend
- +266.1% vs SKIN's -35.9%
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
ESTA ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 27.1%, EPS growth 42.7%, 3Y rev CAGR 9.3%
- 191.0% 10Y total return vs INMD's 105.0%
- 27.1% revenue growth vs SKIN's -10.0%
INMD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.04
- Lower volatility, beta 1.04, Low D/E 1.9%, current ratio 9.88x
- Beta 1.04, current ratio 9.88x
- Lower P/E (9.6x vs 14.9x)
Among these 5 stocks, ALGN doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.1% revenue growth vs SKIN's -10.0% | |
| Value | Lower P/E (9.6x vs 14.9x) | |
| Quality / Margins | 23.3% margin vs SY's -51.8% | |
| Stability / Safety | Beta 1.04 vs SY's 2.05, lower leverage | |
| Dividends | 1.6% yield; 1-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +266.1% vs SKIN's -35.9% | |
| Efficiency (ROA) | 11.8% ROA vs SY's -28.0%, ROIC 13.5% vs -24.1% |
SY vs SKIN vs ESTA vs INMD vs ALGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SY vs SKIN vs ESTA vs INMD vs ALGN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INMD leads in 2 of 6 categories
ALGN leads 1 • SY leads 1 • SKIN leads 0 • ESTA leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INMD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALGN is the larger business by revenue, generating $4.1B annually — 19.4x ESTA's $211M. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to SY's -51.8%. On growth, ESTA holds the edge at +45.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.4B | $296M | $211M | $375M | $4.1B |
| EBITDAEarnings before interest/tax | -$751M | $9M | -$32M | $81M | $790M |
| Net IncomeAfter-tax profit | -$741M | -$6M | -$51M | $87M | $430M |
| Free Cash FlowCash after capex | $0 | $29M | -$57M | $91M | $717M |
| Gross MarginGross profit ÷ Revenue | +51.6% | +64.9% | +69.3% | +77.8% | +67.7% |
| Operating MarginEBIT ÷ Revenue | -53.2% | -3.6% | -18.5% | +21.3% | +14.4% |
| Net MarginNet income ÷ Revenue | -51.8% | -2.0% | -24.2% | +23.3% | +10.5% |
| FCF MarginFCF ÷ Revenue | -6.0% | +9.8% | -27.2% | +24.2% | +17.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.0% | -6.7% | +45.2% | +5.3% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.3% | +38.0% | +92.6% | -30.8% | +23.6% |
Valuation Metrics
INMD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 9.7x trailing earnings, INMD trades at a 67% valuation discount to ALGN's 29.8x P/E. On an enterprise value basis, INMD's 6.9x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $198M | $118M | $2.1B | $882M | $12.1B |
| Enterprise ValueMkt cap + debt − cash | $147M | $264M | $2.3B | $593M | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | -4.68x | -5.69x | -41.88x | 9.73x | 29.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 9.64x | 14.85x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.98x | — |
| EV / EBITDAEnterprise value multiple | — | 7331.15x | — | 6.88x | 13.92x |
| Price / SalesMarket cap ÷ Revenue | 0.92x | 0.39x | 10.03x | 2.38x | 2.99x |
| Price / BookPrice ÷ Book value/share | 1.41x | 2.02x | 90.61x | 1.33x | 3.02x |
| Price / FCFMarket cap ÷ FCF | — | 3.17x | — | 10.46x | 24.57x |
Profitability & Efficiency
ALGN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
INMD delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-2 for ESTA. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ESTA's 11.23x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs SY's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -41.4% | -9.4% | -2.0% | +13.3% | +10.7% |
| ROA (TTM)Return on assets | -28.0% | -1.2% | -15.0% | +11.8% | +6.9% |
| ROICReturn on invested capital | -24.1% | -6.8% | -14.6% | +13.5% | +15.4% |
| ROCEReturn on capital employed | -26.1% | -4.5% | -14.1% | +12.1% | +14.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 4 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.12x | 6.20x | 11.23x | 0.02x | 0.03x |
| Net DebtTotal debt minus cash | -$348M | $146M | $189M | -$289M | -$965M |
| Cash & Equiv.Liquid assets | $588M | $233M | $76M | $303M | $1.1B |
| Total DebtShort + long-term debt | $240M | $379M | $264M | $13M | $114M |
| Interest CoverageEBIT ÷ Interest expense | — | 0.81x | -1.30x | — | 389.13x |
Total Returns (Dividends Reinvested)
SY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ESTA five years ago would be worth $10,061 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, SY leads with a +266.1% total return vs SKIN's -35.9%. The 3-year compound annual growth rate (CAGR) favors SY at 3.6% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +13.1% | -35.0% | +4.6% | -5.9% | +7.9% |
| 1-Year ReturnPast 12 months | +266.1% | -35.9% | +116.5% | -2.1% | -2.2% |
| 3-Year ReturnCumulative with dividends | +11.3% | -91.7% | +6.4% | -60.2% | -45.0% |
| 5-Year ReturnCumulative with dividends | -64.7% | -92.9% | +0.6% | -63.9% | -71.9% |
| 10-Year ReturnCumulative with dividends | -82.9% | -91.6% | +191.0% | +105.0% | +122.8% |
| CAGR (3Y)Annualised 3-year return | +3.6% | -56.4% | +2.1% | -26.4% | -18.1% |
Risk & Volatility
Evenly matched — ESTA and INMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
INMD is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than SY's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ESTA currently trades 86.5% from its 52-week high vs SKIN's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.05x | 2.00x | 1.30x | 1.04x | 1.66x |
| 52-Week HighHighest price in past year | $6.28 | $2.69 | $83.31 | $16.74 | $208.31 |
| 52-Week LowLowest price in past year | $0.80 | $0.76 | $32.75 | $12.72 | $122.00 |
| % of 52W HighCurrent price vs 52-week peak | +48.1% | +33.8% | +86.5% | +83.2% | +80.8% |
| RSI (14)Momentum oscillator 0–100 | 65.7 | 52.1 | 66.8 | 39.8 | 44.6 |
| Avg Volume (50D)Average daily shares traded | 457K | 760K | 455K | 804K | 1.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SY as "Buy", SKIN as "Hold", ESTA as "Buy", INMD as "Buy", ALGN as "Buy". Consensus price targets imply 42.9% upside for SKIN (target: $1) vs -73.5% for SY (target: $1). SY is the only dividend payer here at 1.58% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $0.80 | $1.30 | $85.00 | $16.00 | $203.60 |
| # AnalystsCovering analysts | 5 | 13 | 14 | 11 | 33 |
| Dividend YieldAnnual dividend ÷ price | +1.6% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | — | — |
| Dividend / ShareAnnual DPS | $0.32 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.4% | 0.0% | 0.0% | +14.5% | +3.9% |
INMD leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). ALGN leads in 1 (Profitability & Efficiency). 1 tied.
SY vs SKIN vs ESTA vs INMD vs ALGN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SY or SKIN or ESTA or INMD or ALGN a better buy right now?
For growth investors, Establishment Labs Holdings Inc.
(ESTA) is the stronger pick with 27. 1% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). InMode Ltd. (INMD) offers the better valuation at 9. 7x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate So-Young International Inc. (SY) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SY or SKIN or ESTA or INMD or ALGN?
On trailing P/E, InMode Ltd.
(INMD) is the cheapest at 9. 7x versus Align Technology, Inc. at 29. 8x. On forward P/E, InMode Ltd. is actually cheaper at 9. 6x.
03Which is the better long-term investment — SY or SKIN or ESTA or INMD or ALGN?
Over the past 5 years, Establishment Labs Holdings Inc.
(ESTA) delivered a total return of +0. 6%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: ESTA returned +191. 0% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SY or SKIN or ESTA or INMD or ALGN?
By beta (market sensitivity over 5 years), InMode Ltd.
(INMD) is the lower-risk stock at 1. 04β versus So-Young International Inc. 's 2. 05β — meaning SY is approximately 97% more volatile than INMD relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 11% for Establishment Labs Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SY or SKIN or ESTA or INMD or ALGN?
By revenue growth (latest reported year), Establishment Labs Holdings Inc.
(ESTA) is pulling ahead at 27. 1% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -28. 4% for So-Young International Inc.. Over a 3-year CAGR, ESTA leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SY or SKIN or ESTA or INMD or ALGN?
InMode Ltd.
(INMD) is the more profitable company, earning 25. 3% net margin versus -40. 2% for So-Young International Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -42. 6% for SY. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SY or SKIN or ESTA or INMD or ALGN more undervalued right now?
On forward earnings alone, InMode Ltd.
(INMD) trades at 9. 6x forward P/E versus 14. 9x for Align Technology, Inc. — 5. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SKIN: 42. 9% to $1. 30.
08Which pays a better dividend — SY or SKIN or ESTA or INMD or ALGN?
In this comparison, SY (1.
6% yield) pays a dividend. SKIN, ESTA, INMD, ALGN do not pay a meaningful dividend and should not be held primarily for income.
09Is SY or SKIN or ESTA or INMD or ALGN better for a retirement portfolio?
For long-horizon retirement investors, InMode Ltd.
(INMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +105. 0% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INMD: +105. 0%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SY and SKIN and ESTA and INMD and ALGN?
These companies operate in different sectors (SY (Healthcare) and SKIN (Consumer Defensive) and ESTA (Healthcare) and INMD (Healthcare) and ALGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SY is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; ESTA is a small-cap high-growth stock; INMD is a small-cap deep-value stock; ALGN is a mid-cap quality compounder stock. SY pays a dividend while SKIN, ESTA, INMD, ALGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.